Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloi... (and net income of USD 6.5 billion. Appro...)

HOME >> BIOLOGY >> TECHNOLOGY

Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia

Date:6/13/2008

and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,200 full-time associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

For more information

Additional information regarding Gleevec, Tasigna and Novartis Oncology can be found on the websites http://www.novartisoncologyvpo.com, http://www.gleevec.com, http://www.us.tasigna.com and http://www.novartisoncology.us.

References

1. Cortes J. First report of the TOPS study: A randomized phase III trial

of 400mg vs 800mg imatinib in patients with newly diagnosed, previously

untreated CML in chronic phase using molecular endpoints. Abstract.

13th Congress of the European Hematology Association, Bella Center,

Copenhagen, Denmark, June 12-15, 2008.

2. Larson, R., Druker, B. et al. Imatinib pharmacokinetics and its

correlation with response and safety in chronic phase chronic myeloid

leukemia: a subanalysis of the IRIS study. Blood, Feb 2008.

3. Gleevec(R) (imatinib mesylate) tablets prescribing information. East

Hanover, NJ: Novartis Pharmaceuticals Corporation; Nov 2007.

Media Contacts

Media Only:

Kim Fox

Novartis Oncology

P: +1 862 778 7692

C: +1 917 415 2425

Dana Kahn Cooper

P: +1 732 817 1800

C: +1 732 239 6664

Investors only:

Jill Pozarek

Novartis Corporation

P: +1 212 830 2445

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related biology technology :

1. Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality:
2. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
3. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
4. Major Medical Journal Reports Higher Success, Fewer Complications and Lower Cost Treating DVT With Trellis(R) Isolated Thrombolysis Compared With Catheter-Directed Thrombolysis
5. ChemAxon Launches Marvin and JChem Version 5: Better User Experience, Better Integration, More Flexibility and Higher Performance
6. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
7. Notice of Initial Distribution of Net Settlement Funds
8. Awareness of Genzymes Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected
9. QLT reports initial proof of concept data for punctal plug delivery technology
10. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
11. Ferring Initial Purchase Order and Guaranteed Letter of Credit Launches Five Year Contract

Post Your Comments:

Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloi...(and net income of USD 6.5 billion. Appro...)